A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1197-1207

  Leyland Jones, Brian ^a   Bondarenko, Igor ^b   Nemsadze, Gia ^h   Smirnov, Vitaliy ^d   Litvin, Iryna ^c   Kokhreidze, Irakli ⁱ   Abshilava, Lia ^j   Janjalia, Mikheil ^k   Li, Rubi ^m   Lakshmaiah, Kuntegowda C ⁿ   Samkharadze, Beka ^l   Tarasova, Oksana ^e   Mohapatra, Ranjan Kumar ^o   Sparyk, Yaroslav ^f   Polenkov, Sergey ^g   Vladimirov, Vladimir ^p   Xiu, Liang ^q   Zhu, Eugene ^q   Kimelblatt, Bruce ^q   Deprince, Kris ^q   Safonov, Ilya ^q   Bowers, Peter ^q   Vercammen, Els ^q   more..

^a Avera Health   (United States)

^b Dnipropetrovsk State Medical Academy   (Ukraine)

^c Dnepropetrovsk Regional Oncological Dispensary ^*  (Ukraine)

^d Pediat and Adol Gynecol Dept   (Ukraine)

^e Institute of Medical Radiology   (Ukraine)

^f Chemotherapy Department   (Ukraine)

^g Chernigov Regional Oncology Center   (Ukraine)

^h Institute of Clinical Oncology (LTD K Madichi Mammological Center)   (Ukraine)

ⁱ Martin D Abeloff Laboratory Cancer Research Center   (Ukraine)

^j Chemotherapy and Immunotherapy Clinic Medulla   (Ukraine)

^k Tbilisi Cancer Center   (Georgia)

^l Research Institute of Clinical Medicine   (Georgia)

^m ST LUKE S MEDICAL CENTER   (Philippines)

ⁿ KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^o APOLLO HOSPITALS   (India)

^p Pyatigorsk Oncology Dispensary   (Russian Federation)

^q JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRASTUZUMAB; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAM; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; IRON THERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TUMOR GROWTH; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ODDS RATIO; PATHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; ODDS RATIO; QUALITY OF LIFE; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84963758407     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.5649     Document Type: Article

References (31)

1. Knight K, Wade S, Balducci L: Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 116:11S-26S, 2004 (suppl 7A).
2. Ludwig H, Aapro M, Bokemeyer C, et al: Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 45:1603-1615, 2009.
3. Aapro M, Jelkmann W, Constantinescu SN, et al: Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106:1249-1258, 2012.
4. Cabanillas ME, Kantarjian H, Thomas DA, et al: Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a randomized clinical trial. Cancer 118:848-855, 2012.
5. Cella D, Zagari MJ, Vandoros C, et al: Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21:366-373, 2003.
6. Chang J, Couture F, Young S, et al: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597-2605, 2005.
7. Demetri GD, Gabrilove JL, Blasi MV, et al: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 3:45-51, 2002.
8. Demetri GD, Kris M, Wade J, et al; Procrit Study Group: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998.
9. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-2882, 2001.
10. Glaspy J, Bukowski R, Steinberg D, et al; Procrit Study Group: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234, 1997.
11. Littlewood TJ, Bajetta E, Nortier JW, et al: Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 19:2865-2874, 2001.
12. Moebus V, Jackisch C, Schneeweiss A, et al; AGO Breast Study Group: Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: Randomized clinical trial. J Natl Cancer Inst 105:1018-1026, 2013.
13. Pashos CL, Larholt K, Fraser KA, et al: Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Support Care Cancer 20:159-165, 2012.
14. Pronzato P, Cortesi E, van der Rijt CC, et al; EPOINT- 47 Study Group: Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: Results of a European, multicenter, randomized, controlled trial. Oncologist 15:935-943, 2010.
15. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
16. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005.
17. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008.
18. Bohlius J, Langensiepen S, Schwarzer G, et al: Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498, 2005.
19. Tonelli M, Hemmelgarn B, Reiman T, et al: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. CMAJ 180:E62-E71, 2009.
20. Untch M, von Minckwitz G, Konecny GE, et al; Arbeitsgemeinschaft Gynakologische Onkologie PREPARE investigators: PREPARE trial: A randomized phase III trial comparing preoperative, dosedense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standarddosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 22: 1999-2006, 2011.
21. AaproM, Leonard RC, Barnadas A, et al: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- And/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26:592-598, 2008.
22. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 373: 1532-1542, 2009.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000.
24. Aapro M, Moebus V, Nitz U, et al: Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis. Ann Oncol 26:688-695, 2015.
25. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14-31, 2008.
26. Cao Y: Erythropoietin in cancer: A dilemma in risk therapy. Trends Endocrinol Metab 24:190-199, 2013.
27. Debeljak N, Soĺar P, Sytkowski AJ: Erythropoietin and cancer: The unintended consequences of anemia correction. Front Immunol 5:563, 2014.
28. Farrell F, Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9:18-30, 2004 (suppl 5).
29. Oster HS, Neumann D, Hoffman M, et al: Erythropoietin: The swinging pendulum. Leuk Res 36:939-944, 2012.
30. Szenajch J, Wcislo G, Jeong JY, et al: The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells: From clinic to bench-a critical review. Biochim Biophys Acta 1806:82-95, 2010.
31. Zhou B, Damrauer JS, Bailey ST, et al: Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 124:553-563, 2014.